These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2684309)

  • 1. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
    Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ
    Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.
    Yee GC; Self SG; McGuire TR; Carlin J; Sanders JE; Deeg HJ
    N Engl J Med; 1988 Jul; 319(2):65-70. PubMed ID: 3288872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
    Storb R; Leisenring W; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan KM; Witherspoon R; Pettinger M; Bensinger W; Buckner CD; Clift R; Flowers ME; Hansen JA; Pepe M; Chauncey T; Sanders J; Thomas ED
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):194-201. PubMed ID: 9360781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study.
    Lee KH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Lee JS; Lee JH
    Bone Marrow Transplant; 2004 Oct; 34(7):627-36. PubMed ID: 15300231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dose of total body irradiation (TBI), and GvHD prophilaxis have a crucial role on relapse risk and survival after BMT for leukaemia.
    Frassoni F; Bacigalupo A; Sessarego M; Gualandi F; Lamparelli T; Van Lint MT; Occhini D; Corvò R; Scarpati D; Vitale V
    Bone Marrow Transplant; 1991; 7 Suppl 2():130. PubMed ID: 1878675
    [No Abstract]   [Full Text] [Related]  

  • 10. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.
    Storb R; Deeg HJ; Pepe M; Appelbaum F; Anasetti C; Beatty P; Bensinger W; Berenson R; Buckner CD; Clift R
    Blood; 1989 May; 73(6):1729-34. PubMed ID: 2653461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials.
    Storb R; Deeg HJ; Fisher L; Appelbaum F; Buckner CD; Bensinger W; Clift R; Doney K; Irle C; McGuffin R
    Blood; 1988 Feb; 71(2):293-8. PubMed ID: 3276360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
    Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease.
    Witherspoon RP; Deeg HJ; Lum LG; Ochs HD; Hansen JA; Thomas ED; Storb R
    Transplantation; 1984 May; 37(5):456-61. PubMed ID: 6233764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
    Storb R; Pepe M; Deeg HJ; Anasetti C; Appelbaum FR; Bensinger W; Buckner CD; Cliff RA; Doney K; Hansen J
    Blood; 1992 Jul; 80(2):560-1. PubMed ID: 1627810
    [No Abstract]   [Full Text] [Related]  

  • 17. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients.
    Dieterle A; Gratwohl A; Nizze H; Huser B; Mihatsch MJ; Thiel G; Tichelli A; Signer E; Nissen C; Speck B
    Transplantation; 1990 Jun; 49(6):1093-100. PubMed ID: 2193442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.